Who to call at Xilio Therapeutics, Inc., and when
Fundz watches for the moments Xilio Therapeutics, Inc. starts buying, and tells you who to reach.
- An alert the day Xilio Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Xilio Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Xilio Therapeutics, Inc.. With Fundz connected, it knows.
Xilio Therapeutics, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
www.xiliotx.comAI Executive Summary
AI-powered analysis of 8-K filing content
Xilio Therapeutics stockholders approved the 2025 Stock Incentive Plan and a one-time repricing of certain employee stock options at a special meeting on November 21, 2025. Options held by the CEO, CFO/COO and CMO were reduced to a $1.50 exercise price, which affects equity compensation and potential dilution.
Key Takeaways
Stockholders approved the 2025 Stock Incentive Plan, previously adopted by the Board subject to stockholder approval; the full plan is filed as Exhibit 99.1.
A one-time repricing of certain outstanding employee stock options was approved and implemented after market close on November 21, 2025.
3 more takeaways
Related Filings (7)
7 more filings from Xilio Therapeutics, Inc. in the last 90 days
Filing Overview
What This Means
Xilio Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.